Biogen shares tumble after key exec notes a changeup to pivotal aducanumab study due to 'variability'
With news of Merck’s flagship BACE drug going down to complete failure in a late-stage Alzheimer’s study still reverberating through a dispirited R&D field …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
